P2RX7 and neuroblastoma: Moreover, studies on P2X7 receptor antagonists, anti-oncogenic peptide antibodies, integrin β1 expression, signaling pathways involved and signaling pathway inhibitors (wortmannin, LY-294002), FAK inhibitors (Y15), peptide receptor knockdown, sPEP1 knockdown, acetic acid analogs (dichloroacetate), and the transcription factor Ets 1 must be fully developed to counteract the beneficial effects mediated by oncogenic peptides on NB.